Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39,581 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A molecular switch from tumor suppressor to oncogene in ER+ve breast cancer: Role of androgen receptor, JAK-STAT, and lineage plasticity.
Asemota S, Effah W, Holt J, Johnson D, Cripe L, Ponnusamy S, Thiyagarajan T, Khosrosereshki Y, Hwang DJ, He Y, Grimes B, Fleming MD, Pritchard FE, Hendrix A, Fan M, Jain A, Choi HY, Makowski L, Hayes DN, Miller DD, Pfeffer LM, Santhanam B, Narayanan R. Asemota S, et al. Among authors: he y. Proc Natl Acad Sci U S A. 2024 Oct;121(40):e2406837121. doi: 10.1073/pnas.2406837121. Epub 2024 Sep 23. Proc Natl Acad Sci U S A. 2024. PMID: 39312663
Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer.
Thiyagarajan T, Ponnusamy S, Hwang DJ, He Y, Asemota S, Young KL, Johnson DL, Bocharova V, Zhou W, Jain AK, Petricoin EF, Yin Z, Pfeffer LM, Miller DD, Narayanan R. Thiyagarajan T, et al. Among authors: he y. Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2211832120. doi: 10.1073/pnas.2211832120. Epub 2022 Dec 28. Proc Natl Acad Sci U S A. 2023. PMID: 36577061 Free PMC article.
Identification of a targetable JAK-STAT enriched androgen receptor and androgen receptor splice variant positive triple-negative breast cancer subtype.
Asemota S, Effah W, Young KL, Holt J, Cripe L, Ponnusamy S, Thiyagarajan T, Hwang DJ, He Y, Mcnamara K, Johnson D, Wang Y, Grimes B, Khosrosereshki Y, Hollingsworth TJ, Fleming MD, Pritchard FE, Hendrix A, Khan F, Fan M, Makowski L, Yin Z, Sasano H, Hayes DN, Pfeffer LM, Miller DD, Narayanan R. Asemota S, et al. Among authors: he y. Cell Rep. 2023 Dec 26;42(12):113461. doi: 10.1016/j.celrep.2023.113461. Epub 2023 Nov 17. Cell Rep. 2023. PMID: 37979170 Free PMC article.
Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
Ponnusamy S, He Y, Hwang DJ, Thiyagarajan T, Houtman R, Bocharova V, Sumpter BG, Fernandez E, Johnson D, Du Z, Pfeffer LM, Getzenberg RH, McEwan IJ, Miller DD, Narayanan R. Ponnusamy S, et al. Among authors: he y. Clin Cancer Res. 2019 Nov 15;25(22):6764-6780. doi: 10.1158/1078-0432.CCR-19-1458. Epub 2019 Sep 3. Clin Cancer Res. 2019. PMID: 31481513
Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.
Ponnusamy S, Coss CC, Thiyagarajan T, Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB, Pagadala J, Singh G, Wake RW, Ledbetter C, Tilley WD, Moldoveanu T, Dalton JT, Miller DD, Narayanan R. Ponnusamy S, et al. Among authors: he y. Cancer Res. 2017 Nov 15;77(22):6282-6298. doi: 10.1158/0008-5472.CAN-17-0976. Epub 2017 Oct 4. Cancer Res. 2017. PMID: 28978635 Free PMC article.
39,581 results
You have reached the last available page of results. Please see the User Guide for more information.